Nature Reviews Clinical Oncology最新文献

{"title":"The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC","authors":"Fatemeh Ardeshir-Larijani, Suresh S. Ramalingam","doi":"10.1038/s41571-024-00938-3","DOIUrl":"https://doi.org/10.1038/s41571-024-00938-3","url":null,"abstract":"In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":78.8,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142002772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applications of cell therapy in the treatment of virus-associated cancers","authors":"Keri Toner, Chase D. McCann, Catherine M. Bollard","doi":"10.1038/s41571-024-00930-x","DOIUrl":"https://doi.org/10.1038/s41571-024-00930-x","url":null,"abstract":"<p>A diverse range of viruses have well-established roles as the primary driver of oncogenesis in various haematological malignancies and solid tumours. Indeed, estimates suggest that approximately 1.5 million patients annually are diagnosed with virus-related cancers. The predominant human oncoviruses include Epstein–Barr virus (EBV), Kaposi sarcoma-associated herpesvirus (KSHV), hepatitis B and C viruses (HBV and HCV), human papillomavirus (HPV), human T-lymphotropic virus type 1 (HTLV1), and Merkel cell polyomavirus (MCPyV). In addition, although not inherently oncogenic, human immunodeficiency virus (HIV) is associated with immunosuppression that contributes to the development of AIDS-defining cancers (specifically, Kaposi sarcoma, aggressive B cell non-Hodgkin lymphoma and cervical cancer). Given that an adaptive T cell-mediated immune response is crucial for the control of viral infections, increasing research is being focused on evaluating virus-specific T cell therapies for the treatment of virus-associated cancers. In this Review, we briefly outline the roles of viruses in the pathogenesis of these malignancies before describing progress to date in the field of virus-specific T cell therapy and evaluating the potential utility of these therapies to treat or possibly even prevent virus-related malignancies.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":78.8,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142002770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blinatumomab improves outcomes in adult MRD-negative BCP-ALL","authors":"Diana Romero","doi":"10.1038/s41571-024-00936-5","DOIUrl":"https://doi.org/10.1038/s41571-024-00936-5","url":null,"abstract":"<p>Adults with B cell-precursor acute lymphoblastic leukaemia (BCP-ALL) negative for minimal residual disease (MRD) after induction chemotherapy have a superior prognosis relative to those with MRD⁺ status, although many will eventually have disease relapse. Now, data from the phase III E1910 trial demonstrate that addition of the CD19 × CD3 bispecific T cell engager blinatumomab to consolidation chemotherapy improves overall survival (OS) in this setting.</p><p>Patients received standard-of-care induction chemotherapy. Those with an MRD^– complete response (&lt;0.01% leukaemic cells in bone marrow; 224 of 488 patients) were randomly allocated (1:1) to receive standard-of-care consolidation chemotherapy with or without blinatumomab, followed by standard maintenance therapy in both groups. OS in patients with MRD^– disease was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":78.8,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives","authors":"Antonio Marra,&nbsp;Sarat Chandarlapaty,&nbsp;Shanu Modi","doi":"10.1038/s41571-024-00933-8","DOIUrl":"10.1038/s41571-024-00933-8","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00933-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC","authors":"Diana Romero","doi":"10.1038/s41571-024-00931-w","DOIUrl":"https://doi.org/10.1038/s41571-024-00931-w","url":null,"abstract":"<p>Patients with extensive-stage small-cell lung cancer (ES-SCLC) usually receive platinum-based chemotherapy plus an immune-checkpoint inhibitor (ICI) as first-line therapy, although disease relapse is a concern. Now, data from the phase III ETER701 trial demonstrate that the combination of the anti-angiogenic agent anlotinib plus the anti-PD-L1 antibody benmelstobart and chemotherapy has promising efficacy in this setting.</p><p>Patients were randomly allocated to receive anlotinib plus benmelstobart and chemotherapy (triplet regimen; <i>n</i> = 246), anlotinib plus placebo and chemotherapy (doublet regimen; <i>n</i> = 245) or double placebo plus chemotherapy (the standard of care in China at the time of trial design) (<i>n</i> = 247). Progression-free survival (PFS) and overall survival (OS) were the co-primary end points.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":78.8,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial landscapes of cancers: insights and opportunities","authors":"Julia Chen,&nbsp;Ludvig Larsson,&nbsp;Alexander Swarbrick,&nbsp;Joakim Lundeberg","doi":"10.1038/s41571-024-00926-7","DOIUrl":"10.1038/s41571-024-00926-7","url":null,"abstract":"Solid tumours comprise many different cell types organized in spatially structured arrangements, with substantial intratumour and intertumour heterogeneity. Advances in spatial profiling technologies over the past decade hold promise to capture the complexity of these cellular architectures to build a holistic view of the intricate molecular mechanisms that shape the tumour ecosystem. Some of these mechanisms act at the cellular scale and are controlled by cell-autonomous programmes or communication between nearby cells, whereas other mechanisms result from coordinated efforts between large networks of cells and extracellular molecules organized into tissues and organs. In this Review we provide insights into the application of single-cell and spatial profiling tools, with a focus on spatially resolved transcriptomic tools developed to understand the cellular architecture of the tumour microenvironment and identify opportunities to use them to improve clinical management of cancers. Solid tumours are complex ecosystems comprising many different cell types with spatially structured arrangement. The authors of the Review describe how single-cell and spatial profiling tools have been applied to understand the cellular architecture of the tumour microenvironment. These approaches have potential to improve the way cancer is diagnosed and treated.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41571-024-00926-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-targeted therapies beyond breast cancer — an update","authors":"Jeesun Yoon,&nbsp;Do-Youn Oh","doi":"10.1038/s41571-024-00924-9","DOIUrl":"10.1038/s41571-024-00924-9","url":null,"abstract":"The receptor tyrosine-kinase HER2 (also known as ErbB2) is a well-established therapeutic target in patients with breast or gastric cancer selected on the basis of HER2 overexpression on immunohistochemistry and/or ERBB2 amplification on in situ hybridization. With advances in cancer molecular profiling and increased implementation of precision medicine approaches into oncology practice, actionable HER2 alterations in solid tumours have expanded to include ERBB2 mutations in addition to traditional HER2 overexpression and ERBB2 amplification. These various HER2 alterations can be found in solid tumour types beyond breast and gastric cancer, although few HER2-targeted therapeutic options have been established for the other tumour types. Nevertheless, during the 5 years since our previous Review on this topic was published in this journal, obvious and fruitful progress in the development of HER2-targeted therapies has been made, including new disease indications, innovative drugs with diverse mechanisms of action and novel frameworks for approval by regulatory authorities. These advances have culminated in the recent histology-agnostic approval of the anti-HER2 antibody–drug conjugate trastuzumab deruxtecan for patients with HER2-overexpressing solid tumours. In this new Review, we provide an update on the current development landscape of HER2-targeted therapies beyond breast cancer, as well as anticipated future HER2-directed treatment strategies to overcome resistance and thereby improve efficacy and patient outcomes. Anti-HER2 therapy has revolutionized the treatment of HER2-positive breast cancer. However, HER2 has emerged as a driver of various other cancers and the indications for HER2-targeted therapy have expanded to include diverse HER2-overexpressing as well as HER2-mutant tumour types beyond breast cancer, facilitated by the advent of novel agents with greater potency and distinct mechanisms of action. Some of these agents have demonstrated promising activity even against HER2-low cancers. Herein, Yoon and Oh describe the landscape of HER2 alterations and HER2-targeted drug development beyond breast cancer. They also discuss new insights into mechanisms of resistance and potential strategies by which they might be overcome.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tisotumab vedotin effective in recurrent cervical cancer","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00929-4","DOIUrl":"https://doi.org/10.1038/s41571-024-00929-4","url":null,"abstract":"<p>Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting.</p><p>A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously received 1 (62.8%) or 2 (36.8%) lines of therapy were randomly assigned (1:1) to receive tisotumab vedotin versus investigator’s choice of chemotherapy (including topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed). Overall survival (OS) was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":78.8,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BrECADD raises the bar in classical Hodgkin lymphoma","authors":"David Killock","doi":"10.1038/s41571-024-00928-5","DOIUrl":"10.1038/s41571-024-00928-5","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCMA-directed therapy for early relapsed and/or refractory multiple myeloma.","authors":"Niels W C J van de Donk, Sonja Zweegman","doi":"10.1038/s41571-024-00927-6","DOIUrl":"https://doi.org/10.1038/s41571-024-00927-6","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}